

## A Rare Case- Placental Site Trophoblastic Tumour

\* Dr. Mukti S. Harne, \*\*Dr. A. A Solanke,  
\*\*\*Dr. Rath S. K, \*\*\*\*Dr. Gawali Urmila

\*Resident, \*\*Professor, \*\*\*Professor & Head,  
\*\*\*\*Assistant professor

**Address for Correspondence :** Department of OB & GY, PDVVPF's Medical college, Ahmednagar, Maharashtra.

**Background :** Gestational trophoblastic disease is an umbrella term for a group of pregnancy related disorders arising from abnormal placental trophoblast cells. It may follow either molar pregnancy, non-molar term pregnancy or first-trimester non-molar miscarriage. Persistent gestational trophoblastic disease is potentially fatal, but majority of patients are cured with chemotherapy.

**Case :** 25 year old G4P2L2A1 with 8 months amenorrhea , irregular spotting PV since 5 months. UPT positive. USG suggestive of placenta accreta and intrauterine pregnancy of 7 weeks 3 days with increased vascularity on doppler. She was started on tab. methotaxate 5 mg per day for 4 days by private practitioner and asked to follow up for serial  $\beta$ HCG.  $\beta$ HCG was 16,041 mIU/ml intially, which gradually decreased to 2015 mIU/ml over 4 months. She came to us with 2015 mIU/ml value, where a repeat USG suggestive of the same. Her vitals were stable, systemic examination normal. PS : Cx soft hyperemic, PV : uterus 10 weeks ,AV. Investigations- CBC, LFT, KFT, Chest x ray - normal. Patient was started on chemotherapy. Injection methotrexate 50 ml was given in alteration with injection leucovorin intramuscular for 4 doses. USG was done after 7 days which showed reduced vascularity on Doppler.  $\beta$ HCG was repeated- 527 mIU/ml .She underwent suction and evacuation with 2 blood reserved.

Intraoperatively, copious amount of product was obtained the sample was sent for histopathology examination . Intraoperative bleeding managed with intrauterine packing.  $\beta$ HCG was repeated 48 HRS after evacuation which came to be 17 mIU/ml

**Discussion :** Gestational Trophoblastic Neoplasia (GTN) is a rare disease with varied presentation, and clinicians are still faced with many challenges in management. It includes both benign and malignant forms. Early diagnosis by ultrasound, availability of sensitive  $\beta$ -HCG assays, and introduction of effective

chemotherapy regimens have made this once fatal malignancy curable. GTN is common at extremes of age, less than 15 years and more than 45 years<sup>[1]</sup>. The placental site trophoblastic disease show benign to malignant presentation. It differs from choriocarcinoma with little amount of  $\beta$ -HCG.<sup>[2]</sup> Curettage can lead to uterine perforation because the tumour invades deeply in the myometrium<sup>[3]</sup>. Tumor best treated with hysterectomy<sup>[4]</sup>. Suction and evacuation done in sporadic cases where fertility is desired. Repeat or second uterine evacuation has a role in selected cases of persistent gestational trophoblastic disease where  $\beta$ -HCG is less than 1500 IU/litre, and ultrasound shows significant retained molar tissue. Third evacuation is no longer recommended.<sup>[5,6]</sup>

### Histopathological Result :

Histopathological Report suggestive of persistent gestational trophoblastic disease.

Patient is asked to come for follow up ,monthly for 6month.

**Conclusion :** Risk factors for post molar GTN are Advanced maternal age, Uterine size more than period of gestation, Bilateral theca lutein cyst, Post evacuation uterine haemorrhage / subinvolution. Role of chemotherapy and weekly  $\beta$ -HCG levels. Appropriate diagnosis of PTD with serial  $\beta$ -HCG levels<sup>[7]</sup> and treatment leads to near 100% cure and prevention of neoplastic changes .Anticipating and aggravated approach with patient's compliance played a vital role in saving her of hysterectomy. Multidrug chemotherapy can also be used in case of single drug resistance.<sup>[8]</sup>





Fig. -1 Trophoblastic tissue with fetal pole(in box)



**Fig. -2 USG image showing increased vascularity on doppler**



**Fig. - 3 Pre Suction and evacuation scan**

#### References :

1. N. J. Sebire, R. A. Fisher, M. Foskett, H. Rees, M. J. Seckl, and E. S. Newlands, "Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy," *British Journal of Obstetrics and Gynaecology*, vol. 110, no. 1, pp. 22–26, 2003.
2. Royal College of Obstetricians and gynaecologists, "The management of Gestational Trophoblastic disease," RCOG Green Top Guideline NO. 38, 2009.
3. F. Flam, F. Petterson, and V. Lundstrom, "Medical induction prior to surgical evacuation of Hydatidiform mole. Is there a greater risk of persistent gestational trophoblastic disease?" *European Journal of Obstetrics and Gynecology and Reproductive Biology*, vol. 42, pp. 57–60, 1991.
4. M. Stone and K. D. Bagshawe, "An analysis of the influences of maternal age, gestational age, contraceptive method, and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy," *British Journal of Obstetrics and Gynaecology*, vol. 86, no. 10, pp. 782–792, 1979.
5. M. Pezeshki, B. W. Hancock, P. Silcocks et al., "The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease," *Gynecologic Oncology*, vol. 95, no. 3, pp. 423–429, 2004.
6. N. Pisal, J. Tidy, and B. Hancock, "Gestational trophoblastic disease: is intensive follow up essential in all women?" *British Journal of Obstetrics and Gynaecology*, vol. 111, no. 12, pp. 1449–1451, 2004.
7. N. J. Sebire, M. Foskett, D. Short et al., "Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit," *British Journal of Obstetrics and Gynaecology*, vol. 114, no. 6, pp. 760–762, 2007.
8. Dobson LS1, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. *Br J Cancer*. 2000 May;82(9):1547-52.